The four groups of DLBCL they established through use of their algorithm were “MCD” defined by MYD88 and CD79B mutations, “BN2” defined by BCL6 fusions and NOTCH2 mutations, “N1” defined by NOTCH1 mutations, and “EZB” defined by EZH2 and BCL2 translocations. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.